Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

O Estudo Lóa: Uma Breve Intervenção Digital para Mulheres com Memórias Intrusivas na Coorte SAGA

10 de novembro de 2026 atualizado por: Arna Hauksdottir, University of Iceland

O Estudo Lóa: Um Teste de Controle Randomizado de uma Intervenção Digital Breve para Apoiar Mulheres que Experimentam Memórias Intrusivas de Eventos Traumáticos Durante Suas Vidas Da Coorte SAGA

Intrusive memories are sensory memories of a traumatic event(s) that spring to mind involuntarily, and can evoke strong emotions and disrupt functioning in daily life. Previous research has indicated that a brief cognitive intervention can prevent the development of intrusive memories as well as reduce the number of intrusive memories of long-standing trauma. Initial pilot work (using case studies and a pilot study, ClinicalTrials.gov identifier: NCT05089058) with women in Iceland indicates that the intervention is acceptable and feasible.

This randomised controlled trial will compare 3 arms to investigate if access to a cognitive task - either a brief self-guided imagery-competing task or a brief self-guided psychoeducation and signposting task - versus treatment as usual, can reduce the number of intrusive memories in week 5 (i.e., between-groups comparison), controlling for the number of intrusive memories in the baseline week.

The effect on the number of intrusive memories in week 5 (primary outcome), and other symptoms of post-traumatic stress, sleep and cognitive functioning will be tested.

This study is funded by the Icelandic Research Fund (11709-0270) and (200095-5601) and The Oak Foundation (OCAY-18-442).

Visão geral do estudo

Descrição detalhada

Participants will be recruited from the Stress and Gene Analysis (SAGA) Cohort, a population-based, longitudinal study of Icelandic women (www.afallasaga.is, see selected publications in the reference box below).

A statistical analysis plan will be prepared prior to the first interim analysis using both frequentist and Bayesian analyses for statistical inference.

Regular monitoring will be performed by Vistor to verify that the study is conducted, and data are generated, documented and reported in compliance with the protocol, good clinical practice (GCP) and the applicable regulatory guidelines.

Tipo de estudo

Intervencional

Inscrição (Real)

320

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Reykjavik, Islândia, 102
        • University of Iceland, Sæmundargata 12

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 73 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Part of the SAGA cohort
  • Aged 18 or above.
  • Able to read, write and speak in Icelandic.
  • Have internet access.
  • Willing to be contacted remotely and having access to a smartphone or computer
  • Experience 3 or more intrusive memories in the past week
  • Willing to monitor intrusive memories in everyday life
  • Willing and able to provide informed consent and complete study procedures
  • Willing and able to be contacted by the research team during the study period.
  • Have not taken part in a previous study of this intervention from this research team (e.g., the Loa case series, feasibility trial or pilot RCT).

Exclusion Criteria:

  • Have fewer than three intrusive memories during the baseline week.
  • Suicide risk in the initial assessment (response of 'nearly every day' to item 9 on PHQ-9).
  • Those undergoing other treatments for post-traumatic stress disorder (PTSD) or its symptoms will not be excluded, so the study will be as inclusive as possible.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Brief imagery-competing task

Access to a brief imagery-competing task for 24 weeks (with optional researcher support during the study)

Two digital self-guided sessions of a brief digital imagery-competing task. A memory cue followed by playing a computer game with mental rotation instructions.

Experimental: Brief psychoeducation and signposting task

Access to psychoeducation and signposting regarding resources for psychological trauma in Iceland for 24 weeks (with optional researcher support during the study)

Two digital self-guided sessions and access to psychoeducation and signposting regarding resources for psychological trauma in Iceland.

Outro: Treatment as usual (TAU)

Routine care that participants would otherwise receive if having intrusive memories of traumatic events.

Routine care that participants would otherwise receive if having intrusive memories of traumatic events

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of intrusive memories of traumatic event(s)
Prazo: Week 5 (all arms) controlling for run-in/baseline week

The number of intrusive memories of traumatic events recorded by participants in a brief daily online intrusive memory diary for 7 days.

Week 5 (all arms) controlling for run-in/baseline week

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of intrusive memories of the traumatic event(s)
Prazo: Week 12 and week 24 follow-ups (all arms) controlling for run-in/baseline week

The number of intrusive memories of traumatic events recorded by participants in a brief daily online intrusive memory diary for 7 days.

Week 12 and week 24 follow-ups (all arms) controlling for run-in/baseline week
The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)
Prazo: Baseline, week 5, week 12 and week 24 follow-ups

A 20-item questionnaire assessing the severity of PTSD symptoms corresponding to the DSM-5 criteria for PTSD. Items are rated on a 5-point Likert scale ranging from 0 ("not at all") to 4 ("extremely"). Scores are summed to give a total severity score (ranging 0 to 80).

Baseline, week 5, week 12 and week 24 follow-ups
The Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A)
Prazo: Baseline, week 5, week 12 and week 24 follow-ups

A 7-item questionnaire assessing the frequency of disruptive nocturnal behaviours (e.g., acting out dreams, episodes of terror or screaming). Respondents report symptoms over the past month on a 4-point Likert scale, ranging from 0 ("never in the past month") to 3 ("three or more times each week"). Total score ranges from 0 to 21 with higher scores indicating worse symptoms.

Baseline, week 5, week 12 and week 24 follow-ups
Cognitive Functions Scale
Prazo: Baseline, week 5, week 12 and week 24 follow-ups

An 11 item questionnaire about cognitive functions in particular memory and concentration. Items are rated on a 5-point scale, from 1 ("every day") to 5 ("never"). Total scores range from 11 to 55; higher scores indicate less concentration and memory difficulties.

Baseline, week 5, week 12 and week 24 follow-ups

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
The Patient Health Questionnaire-9 (PHQ-9)
Prazo: Baseline, week 5, week 12 and week 24 follow-ups

A 9-item questionnaire assessing depression symptoms and their severity. Items are scored from 0 ( "not at all") to 3 ( "nearly every day"). The total score is the sum of all items and ranges from 0 to 27.

Baseline, week 5, week 12 and week 24 follow-ups
The Generalized Anxiety Disorder-7 scale (GAD-7)
Prazo: Baseline, week 5, week 12 and week 24 follow-ups

A 7-item questionnaire assessing severity of anxiety symptoms. Items are rated for how often they have bothered the respondent over the last two weeks, from 0 ("not at all") to 3 ("nearly every day"). The total score is the sum of all items and ranges from 0 to 21.

Baseline, week 5, week 12 and week 24 follow-ups
The Sheehan Disability Scale (SDS)
Prazo: Baseline, week 5, week 12 and week 24 follow-ups

A questionnaire assessing functional impairment across three domains: (1) Work/school, (2) social, and (3) family life. Domains are measured on an 11-point Likert scale, ranging from 0 ("not at all") to 10 ("extremely"). The scale is adapted to assess functional impairment associated with intrusive memories. The total score is the sum of all items and ranges from 0 to 30.

Baseline, week 5, week 12 and week 24 follow-ups
Quality of Life Scale (QOLS)
Prazo: Baseline, week 5, week 12 and week 24 follow-ups

16-item measure to assess quality of life on a 7-point Likert scale, ranging from 7 ("delighted") to 1 ("terrible"). The domains that are assessed are the following: (1) Social and community activities, (2) material and physical wellbeing, (3) relationships with other people, (4) personal development and fulfilment, and (5) recreation. The total score is the sum of all items and ranges from 16 to 112.

Baseline, week 5, week 12 and week 24 follow-ups
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
Prazo: Baseline, week 5, week 12 and week 24 follow-ups

A 12-item questionnaire assessing difficulties due to health conditions, including mental or emotional problems (with reference to intrusive memories). Respondents rate how much difficulty they have had in each area in the past 30 days, from 0 ("none") to 4 ("extreme or cannot do"). The overall score is calculated as a percentage of the maximum possible score (i.e., 48 points). Lower scores indicate better functioning.

Baseline, week 5, week 12 and week 24 follow-ups
General Impact of intrusive memories
Prazo: Baseline, week 5, week 12 and week 24 follow-ups

2-items measuring the general impact of intrusive memories in terms of level of distress and vividness associated with the intrusions on a 11-point scale (ranging from 0 to 10), rated at the end of each diary week. High scores indicate higher levels of distress/vividness.

Baseline, week 5, week 12 and week 24 follow-ups
Acceptability and feasibility
Prazo: Week 5

Four questions to assess acceptability and feasibility of the both interventions. Rated on a 11-point scale (0 to 10) to measure the extent to which the individual would recommend the intervention and whether they consider it to be an acceptable way to reduce the frequency of intrusive memories. In addition, in this study, we include 1 item on the type of digital device used and 2 open-ended questions about the experience of using the digital platform.

Week 5
Adverse events (AEs)
Prazo: Week 5, week 12 and week 24 follow-ups

A free-text response field measuring the occurrence of any health problems since the last contact.

Week 5, week 12 and week 24 follow-ups
Credibility/Expectancy Questionnaire
Prazo: Right after randomization

6-item questionnaire that rates to what degree the participant finds the intervention credible on a 11-point scale from 0 to 10. High scores indicate greater credibility.

Right after randomization
Feedback Questionnaire
Prazo: Week 5

A 7-item questionnaire will assess participants' experience of using the intervention. The first five items assess how easy, helpful, distressing, burdensome and interesting participants found the intervention. This was assessed on a 11-point scale ranging from 0 ("not at all") to 10 ("very"). The last 2 free-text items ask how the brief cognitive task could be improved, and for any other comments.

Week 5

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Arna Hauksdóttir, PhD, University of Iceland
  • Investigador principal: Emily Holmes, PhD, Uppsala University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

30 de outubro de 2023

Conclusão Primária (Real)

15 de abril de 2026

Conclusão do estudo (Real)

14 de setembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

27 de abril de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

27 de abril de 2023

Primeira postagem (Real)

8 de maio de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 22-186

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Anonymised research data will be made available on Open Science Framework (OSF) indefinitely

Prazo de Compartilhamento de IPD

The aim is to share the Study Protocol and Statistical Analysis Plan upon the last participant completing the last visit. Supporting information mentioned above will be shared indefinitely and with no end date on the Open Science Framework (OSF) platform. The results of the study will be shared through open-access publications.

Critérios de acesso de compartilhamento IPD

Anonymised research data will be made available on Open Science Framework (OSF) indefinitely.

OSF is an open-source web application that is freely accessible to the public and scientific community

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever